BIIB Q1 2021 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q1 2021 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.7B-23.8% YoY

Gross Profit

$2.2B82.3% margin

Operating Income

$974M36.2% margin

Net Income

$410M15.2% margin

EPS (Diluted)

$2.69

QoQ Revenue Growth

-5.6%

Cash Flow

Operating Cash Flow

$769M

Free Cash Flow

$676M

Stock-Based Comp.

$70M

Balance Sheet

Total Assets

$23.9B

Total Liabilities

$13.2B

Stockholders' Equity

$10.7B

Cash & Equivalents

$1.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.7B	$3.5B	-23.8%
Gross Profit	$2.2B	$3.1B	-28.1%
Operating Income	$974M	$1.8B	-46.5%
Net Income	$410M	$1.4B	-70.7%

Revenue Segments

MS Product Revenues

$1.5B43%

Fumarate

$553M16%

SPINRAZA

$521M15%

TYSABRI product

$503M15%

Interferon

$401M12%

Geographic Segments

Non-US

$1.3B59%

UNITED STATES

$900M41%